Fas/Fas ligand and hematopoietic progenitor cells

Current Opinion in Hematology

Volumn 5, Issue 3, 1998, Pages 163-165

  Niho, Yoshiyuki ^a   Asano, Yoshinobu ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CELL SURFACE RECEPTOR; FAS ANTIGEN; FAS LIGAND;

ANTIGEN EXPRESSION; APLASTIC ANEMIA; APOPTOSIS; BONE MARROW SUPPRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LYMPHOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0031858324     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199805000-00002     Document Type: Short Survey

References (23)

1. Nagata S, Golstein P: The Fas death factor. Science 1995, 267: 1449-1456. Reviews the Fas/Fas ligand system.
2. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguch N: Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994, 84: 1201-1208.
3. Maciejewski J, Selleri C, Anderson S, Young N: Fas antigen expression on CD34+ human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine mediated hematopoietic suppression in vitro. Blood 1995, 85: 3183-3190.
4. + cells freshly isolated from bone marrow did not express Fas antigen. However, functional expression of Fas antigen was induced by addition of interferon gamma and TNF-α. These findings suggest that the suppression of hematopoiesis by negative hematopoietic regulator may be mediated in part by Fas antigen induction.
5. Nagafuji T, Takanaka K, Shibuya T, Harada M, Niho Y: Fas antigen (CD95) and hematopoietic progenitor cells. Leuk Lymphoma 1996, 24: 43-56.
6. + cells. Br J Haematol 1997, 97: 356-365.
7. + cells expanded in the presence of positive hematopoietic regulators. Induction of Fas antigen and downregulation of bcl-2 may be expressed as part of the differentiation program of hematopoietic cells and may be involved in the regulation of hematopoiesis.
8. Yamane T, Hino M, Tatsumi N: Change in Fas antigen expression during differentiation of CD34-positive cells isolated from peripheral blood stem cell harvest samples. Eur J Haematol 1997, 58: 289-290.
9. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E: Expression of Fas/CD95 and bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood 1996, 88: 2013-2025.
10. Drappa J, Vaishnaw A, Sullivan K, Chu J, Sikon K: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996, 335: 1643-1649. Describes Fas gene mutations in patients with Canale-Smith syndrome.
11. + cells derived from patients with aplastic anemia. These results suggest that the Fas/Fas ligand is involved in the pathophysiology of bone marrow failure.
12. Mori T, Ando K, Tanaka K, Ikeda Y, Koga Y: Fas-mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Blood 1997, 89: 3565-3575.
13. + cells from human immunodeficiency virus-infected persons: Differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996, 87: 4959-4966.
14. Bouscary D, Vos JO, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M: Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndrome. Leuekmia 1997, 11: 839-845.
15. DiGiuseppe JA, Kastan MB: Apoptosis in haematological malignancies. J Clin Pathol 1997, 50: 361-364.
16. Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG: Expression and function of CD95 (Fas/Apo-1) in leukaemia-lymphoma tumour lines. Br J Haematol 1997, 96: 584-593.
17. Min YH, Lee S, Lee JW, Chong SY, Hahn JS, Ko YW: Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br J Hematol 1996, 93: 928-930. Investigations of Fas antigen expression on acute myeloid leukemia cells obtained from 30 patients. Low Fas antigen expression was associated with a low complete remission rate after induction chemotherapy.
18. Selleri C, Sato T, Vecchio LD, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP: Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-γ in chronic myelogenous leukemia. Blood 1997, 89: 957-964.
19. Landowski TH, Gleason-Guzman MC, Dalton WS: Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997, 89: 1854-1861. Drug-resistant cell lines were also resistant to Fas-mediated apoptosis. This finding may have clinical implications in the development of strategies for treatment of resistant hematologic malignaicies.
20. Baiocchi RA, Khatri VP, Lindemann MJ, Ross ME, Papoff G, Caprio AJ, Caprio TV, Fenstermaker R, Ruberti G, Bernstein ZP, Caligiuri MA: Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Blood 1997, 90: 1734-1746.
21. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nature Med 1996, 2: 317-322. Measurement of Fas ligand serum levels using enzyme-linked immunosorbent assay. Sera from healthy persons did not contain a detectable level of Fas ligand, whereas that from patients with large granular lymphocyte leukemia and natural killer cell lymphoma did.
22. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, Nagata S, Kanatani Y, Wakimoto N, Nagata N, Motoyoshi K: An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 1996, 94: 379-382.
23. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, Geley S, Kofler R, Greil R: Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997, 90: 12-20.